If you’ve been following my work, you may have recently read my article on geranylgeraniol (GG) and its remarkable ability to reverse statin-induced muscle pain where CoQ10 has failed. Today, I want to share another critical application of this same compound — one that could help prevent a devastating condition that has left many patients with dead jaw bone and no effective treatment options. The condition is called bisphosphonate-related osteonecrosis of the jaw, or BRONJ for short. And the solution, once again, is GG.
What Are Bisphosphonates and Who Takes Them?
Bisphosphonates are a class of drugs prescribed primarily for osteoporosis and for preventing bone complications in cancer patients. You may know them by brand names like Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate), and Zometa or Reclast (zoledronic acid).
These drugs work by inhibiting osteoclasts, the cells responsible for breaking down old bone. By suppressing bone resorption, bisphosphonates can increase bone density and reduce fracture risk. For cancer patients with bone metastases, they can help prevent skeletal complications.
Millions of people take these medications. In fact, bisphosphonates are among the most commonly prescribed drugs for postmenopausal women with osteoporosis. But like all drugs, they come with risks, and one of the most serious is osteonecrosis of the jaw.
The Horror of Jaw Bone Death
Osteonecrosis literally means “bone death.” When it occurs in the jaw, the bone tissue dies and becomes exposed through the gums, failing to heal. Patients develop painful, exposed bone in their mouth that can become infected, lead to tooth loss, and in severe cases require surgical removal of portions of the jaw.
The condition is diagnosed when a patient has exposed jaw bone that doesn’t heal within eight weeks, has a history of taking bisphosphonates or similar medications, and has no history of radiation therapy to the jaw area.
What makes BRONJ particularly insidious is that there is currently no reliable cure. Once the jaw bone dies, treatment options are limited to managing symptoms, controlling infection, and in some cases surgical debridement or removal of dead bone. Prevention is the only truly effective strategy.
The condition often develops after dental procedures — tooth extractions, implant placement, or other invasive dental work. This is why dentists now routinely ask patients about bisphosphonate use before performing procedures, and why some recommend “drug holidays” before dental surgery.
But what if there was a way to protect the jaw bone while still taking these medications? What if the same compound that reverses statin muscle damage could also prevent bisphosphonate jaw damage?
Same Mechanism, Same Solution
Here’s the key insight that connects these two seemingly different conditions: bisphosphonates and statins work through the same biochemical pathway.
Both drug classes inhibit enzymes in the mevalonate pathway. Statins block HMG-CoA reductase at the top of the pathway. Bisphosphonates — specifically the nitrogen-containing bisphosphonates like zoledronic acid — block farnesyl pyrophosphate synthase further down the pathway.
The end result is the same: depletion of geranylgeranyl pyrophosphate (GGPP), the activated form of GG. And when GGPP is depleted, the process of protein prenylation — essential for normal cell function — is impaired.
In muscle cells, this manifests as the muscle pain, weakness, and fatigue that statin patients experience. In the jaw bone, where there’s constant remodeling activity and exposure to oral bacteria, this manifests as impaired healing and eventual bone death.
A 2022 review published in Frontiers in Pharmacology1 explained the connection clearly: “Nitrogen-containing bisphosphonates suppress osteoclastic resorption by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway, leading to deficiency of the substrate for GTPase prenylation. The bone remodeling process is uncoupled, subsequently impairing bone healing and causing ONJ.”
The review went on to note that “targeted administration of geranylgeraniol (GGOH) represents a promising approach to mitigate BRONJ because GGOH is a substrate for GTPase prenylation.”
GG Reverses Bisphosphonate Damage to Jaw Cells
Multiple studies have demonstrated that GG can reverse the cellular damage caused by bisphosphonates in exactly the cell types that are critical for jaw bone health.
A 2011 study published in Oral Oncology2 was among the first to show that GG could reverse the negative biological effects of nitrogen-containing bisphosphonates on endothelial cells (which form blood vessels), fibroblasts (which form connective tissue), and osteogenic cells (which form bone). The researchers found that GG restored the viability and migration capacity of these cells after bisphosphonate treatment.
A 2021 study published in Frontiers in Cell and Developmental Biology3 investigated the specific mechanism by which bisphosphonates cause jaw bone problems. The researchers found that zoledronic acid (a potent bisphosphonate) both promoted the death of osteocytes (bone cells) and inhibited the ability of macrophages to clear dead cells — a process called efferocytosis that’s essential for proper healing.
Critically, the study found that “supplement with geranylgeraniol (GGOH), a substrate analog for geranylgeranylation of Rac1, could restore Rac1 homeostasis and rescue macrophage efferocytosis.” Rac1 (along with a closely related protein called Rac2) acts like an on-off switch that helps immune cells move, attach to damaged tissue, and clear away dead cells so healing can occur.
These proteins need to attach to cell membranes to work properly, and they need geranylgeraniol to do that. When bisphosphonates block this process, Rac signaling breaks down and immune cells cannot clean up damaged tissue. In other words, GG restored the normal healing process that bisphosphonates had disrupted.
A 2020 study4 examined the effects of zoledronic acid and GG on angiogenic (blood vessel-forming) gene expression in human osteoclasts. The researchers found that bisphosphonate treatment altered the expression of multiple genes involved in blood vessel formation — a key factor in bone healing. Addition of GG resulted in reduction of these altered gene expressions, suggesting it could help normalize the angiogenic response.
GG in Bone Cement Promotes Healing
Perhaps most exciting is a 2024 study published in the Journal of Oral Biology and Craniofacial Research5 that tested GG in an actual model of medication-related osteonecrosis of the jaw.
Researchers incorporated GG into bone cement pellets and tested their effects both in cell culture and in animals. They found that GG released from the bone cement increased osteoclast survival and metabolic activity and promoted resorption of calcified substrate — essentially restoring normal bone remodeling function.
In the animal model, released GG “limited the effects of the bisphosphonate and promoted healing.” The researchers noted that “GGOH from the infused cement carrier stabilizes bone structure and restores the ability of osteoclasts to remodel.”
The conclusion was encouraging: “These initial findings point to GGOH in a bone cement carrier as a useful therapeutic approach to prevent or mitigate the pathogenesis of MRONJ.”
While this specific delivery method (bone cement) is a clinical application that would need to be performed by a dental surgeon, the underlying principle is clear: GG can reverse bisphosphonate-induced damage to the cells responsible for jaw bone health and healing.
The Connection to Statin Myopathy
If you read my previous article on GG for statin-induced muscle problems, you’ll recognize the pattern. Both statins and bisphosphonates:
1. Inhibit the mevalonate pathway
2. Deplete geranylgeranyl pyrophosphate (GGPP)
3. Impair protein prenylation
4. Cause tissue damage (muscle or bone) through this mechanism
5. Can be counteracted by GG supplementation
This isn’t a coincidence — it’s biochemistry. These drugs work through the same fundamental mechanism, which is why they cause related problems and why the same solution addresses both.
The research on GG for statin myopathy is more advanced, with multiple in vivo studies and meta-analyses confirming that CoQ10 doesn’t work while GG does. The research on GG for BRONJ is still developing, with most studies being in vitro (cell culture) or in animal models. But the consistency of the findings across both conditions strongly supports the underlying mechanism.
Who Should Consider GG Supplementation?
Based on the available evidence, GG supplementation makes particular sense for:
• People taking bisphosphonates for osteoporosis — If you’re on Fosamax, Boniva, Actonel, or similar medications, GG supplementation may help protect your jaw bone, especially if you need dental procedures.
• Cancer patients receiving bisphosphonate therapy — High-dose intravenous bisphosphonates like Zometa carry a higher risk of BRONJ. Supplementation with GG could provide protective benefits.
• Anyone planning dental work while on bisphosphonates — Tooth extractions and implant placement are known triggers for BRONJ. GG supplementation before, during, and after dental procedures may help support normal healing.
• People taking statins who also take bisphosphonates — Many older adults take both drug classes. Both deplete GG through the same pathway. The combined depletion makes supplementation even more important.
Practical Recommendations
The practical recommendations for GG supplementation in the context of bisphosphonate use are similar to those for statin use:
• Dosing — 150 mg to 300 mg daily appears to be the range used in research.
• Form — Trans-geranylgeraniol from annatto seeds (often sold as “GG-Gold” or similar branded forms) has been the most studied.
• Timing around dental procedures — If you’re planning dental work, consider starting GG supplementation several weeks before the procedure and continuing during healing. Discuss this with your dentist and physician.
• Duration — Unlike some supplements that are taken only when symptomatic, GG supplementation may be most valuable as ongoing support while taking bisphosphonates, given that these drugs can persist in bone tissue for years.
• Safety — GG has demonstrated an excellent safety profile in research. It does not appear to interfere with bisphosphonates’ bone-building effects, similar to how it doesn’t interfere with statins’ cholesterol-lowering effects.
A Unified Approach to Mevalonate Pathway Support
The story of geranylgeraniol is really a story about understanding biochemistry rather than just treating symptoms. When we recognize that both statins and bisphosphonates deplete the same critical compound — and that this depletion causes problems in different tissues depending on which drug you’re taking — we can adopt a unified approach to protection.
• For statin users — GG addresses the root cause of muscle symptoms that CoQ10 couldn’t solve.
• For bisphosphonate users — GG supports the jaw bone health that these drugs compromise.
• For people taking both — GG replenishes what both drug classes deplete.
This is the kind of integrative thinking that conventional medicine often misses. Rather than treating statin myopathy and bisphosphonate jaw necrosis as completely separate conditions requiring separate solutions, we can recognize their common cause and address them together.
If you’re taking either statins or bisphosphonates — or especially if you’re taking both — GG deserves serious consideration as part of your supplement regimen. The research is clear, the mechanism is understood, and the safety profile is excellent. Discuss it with a healthcare provider familiar with integrative approaches, and take control of protecting your muscles and bones from pharmaceutical side effects.
FAQ
Q: What is bisphosphonate-related osteonecrosis of the jaw (BRONJ)?
A: BRONJ is a serious condition in which sections of jaw bone lose blood supply, die, and fail to heal. It occurs in some people who take bisphosphonate drugs for osteoporosis or cancer, especially after dental procedures such as tooth extractions. Once established, there is no consistently effective treatment, which makes prevention critical.
Q: How do bisphosphonates cause jaw bone damage?
A: Bisphosphonates block enzymes in the mevalonate pathway, a metabolic pathway your body uses to produce essential compounds. This blockade depletes geranylgeranyl pyrophosphate (GGPP), which cells need for protein prenylation, a process required for normal bone remodeling, immune cleanup, blood vessel growth, and tissue repair.
Q: Why does geranylgeraniol (GG) matter in BRONJ?
A: GG replenishes GGPP, the compound depleted by bisphosphonates. Research shows GG restores normal function in osteoclasts, osteoblasts, fibroblasts, endothelial cells, and immune cells that support jaw bone healing. By correcting the underlying biochemical disruption, GG targets the root cause rather than symptoms.
Q: What does research show about GG and jaw bone healing?
A: Cell and animal studies report that GG reverses bisphosphonate-induced cell death, restores immune cell cleanup of damaged tissue, and normalizes blood vessel-related gene activity. A 2024 animal study showed GG delivered through bone cement promoted bone remodeling and healing in a model of medication-related osteonecrosis of the jaw.
Q: Who may benefit most from GG supplementation?
A: Evidence suggests GG may help people who take bisphosphonates for osteoporosis or cancer, especially if you plan dental procedures or also take statins, which deplete GG through the same pathway. Human clinical trials remain limited, so you should discuss supplementation with your dentist and physician before use.
Test Your Knowledge with Today’s Quiz!
Take today’s quiz to see how much you’ve learned from yesterday’s Mercola.com article.
Which statement about prebiotics is true?
Dutch 
English 
German 
Polish 
Swedish 
French 
Ukrainian